Q-omics provides the consensus-scored DCAF11 profile across patient tissues and cancer cell-line models. DCAF11 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DCAF11 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DCAF11 RNA expression shows 19,686 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where DCAF11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAF11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAF11 survival associations across molecular data types. DCAF11 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (10) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAF11 RNA expression–survival associations across cancer types. High DCAF11 expression shows favorable associations in KIRC, MESO, UVM, KIRP, UCS and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DCAF11 RNA expression.
This table summarizes DCAF11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DCAF11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAF11 shows lower tumor expression in KIRC, COAD, KICH, THCA and LUAD and higher tumor expression in BRCA. The KIRC box plot shows higher DCAF11 RNA expression in normal versus tumor tissue (log2 FC = −1.190, t-test p < 0.001).
This table shows molecular features associated with DCAF11 in patient tissues and cancer cell lines. In patient samples, DCAF11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DCAF11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
